SCHEMBL1850352

SCHEMBL1850352

CC(NC(=O)c1cccc(-c2n[nH]cc2-c2ccncc2)c1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 12/20 0.58
ROCK2 O75116 12/20 0.58
MAPK1 P28482 8/20 0.58
PRKG1 Q13976 5/20 0.58
RPS6KA5 O75582 4/20 0.58
PRKACA P17612 4/20 0.58
RPS6KB1 P23443 4/20 0.58
CDK2 P24941 4/20 0.58
GSK3A P49840 4/20 0.58
GSK3B P49841 4/20 0.58
PRKX P51817 4/20 0.58
PRKCD Q05655 4/20 0.58
PRKG2 Q13237 4/20 0.58
PKN2 Q16513 4/20 0.58
CDC42BPA Q5VT25 4/20 0.58
CLK4 Q9HAZ1 4/20 0.58
SGK2 Q9HBY8 4/20 0.58
AKT1 P31749 3/20 0.58
RPS6KA3 P51812 3/20 0.58
CDK1 P06493 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1853803 0.90 ROCK2 (0.54) ROCK1ROCK2MAPK1PRKG1RPS6KA5
SCHEMBL1848838 0.83 ROCK2 (0.47) ROCK2CSNK1DCHEK1
SCHEMBL1849102 0.83 GAA (0.53) ROCK1ROCK2MAPK1MAPK3
SCHEMBL1851210 0.82 HDAC8 (0.51) AURKB
SCHEMBL1850045 0.81 SIRT2 (0.54) ROCK1ROCK2RPS6KB1GSK3AGSK3B
SCHEMBL27490296 0.81 ROCK1 (0.60) ROCK1ROCK2MAPK1PRKG1RPS6KA5
SCHEMBL27813525 0.81 MAP2K4 (0.52) ROCK2MAPK1AURKBCSNK1DALDH1A1
SCHEMBL1850444 0.81 AURKA (0.47) ROCK1ROCK2MAPK1MAPK3CYP3A4
SCHEMBL1846331 0.81 NEK1 (0.43) ROCK1ROCK2AURKB
Hydrochloric Acid SCHEMBL1848275 0.80 MAP2K4 (0.51) ROCK2MAPK1AURKBCSNK1DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
CN-102105459-B 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2014-09-10 CN disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
CN-102105459-A 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2011-06-22 CN disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 ROCK1 617/4885ROCK2 648/4885MAPK1 103/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 ROCK1 617/4885ROCK2 648/4885MAPK1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.